{"id":"https://openalex.org/W2789470100","doi":"https://doi.org/10.2147/ijn.s124992","title":"In vitro analysis of PARP inhibitor nanoformulations","display_name":"In vitro analysis of PARP inhibitor nanoformulations","publication_year":2018,"publication_date":"2018-03-01","ids":{"openalex":"https://openalex.org/W2789470100","doi":"https://doi.org/10.2147/ijn.s124992","mag":"2789470100","pmid":"https://pubmed.ncbi.nlm.nih.gov/29593397","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5863639"},"language":"en","primary_location":{"id":"doi:10.2147/ijn.s124992","doi":"https://doi.org/10.2147/ijn.s124992","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ijn.s124992","pdf_url":"https://www.dovepress.com/getfile.php?fileID=41002","source":{"id":"https://openalex.org/S101287785","display_name":"International Journal of Nanomedicine","issn_l":"1176-9114","issn":["1176-9114","1178-2013"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Nanomedicine","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.dovepress.com/getfile.php?fileID=41002","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5033547791","display_name":"Paige Baldwin","orcid":"https://orcid.org/0000-0002-0146-7177","observed_orcids":["https://orcid.org/0000-0002-0146-7177"]},"institutions":[{"id":"https://openalex.org/I12912129","display_name":"Northeastern University","ror":"https://ror.org/04t5xt781","country_code":"US","type":"education","lineage":["https://openalex.org/I12912129"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paige Baldwin","raw_affiliation_strings":["Nanomedicine Science and Technology Center, Northeastern University, Boston, MA, USA"],"raw_orcid":"https://orcid.org/0000-0002-0146-7177","affiliations":[{"raw_affiliation_string":"Nanomedicine Science and Technology Center, Northeastern University, Boston, MA, USA","institution_ids":["https://openalex.org/I12912129"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020321227","display_name":"Shifalika Tangutoori","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I12912129","display_name":"Northeastern University","ror":"https://ror.org/04t5xt781","country_code":"US","type":"education","lineage":["https://openalex.org/I12912129"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shifalika Tangutoori","raw_affiliation_strings":["Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA, USA","Nanomedicine Science and Technology Center, Northeastern University, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Nanomedicine Science and Technology Center, Northeastern University, Boston, MA, USA","institution_ids":["https://openalex.org/I12912129"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101987852","display_name":"Srinivas Sridhar","orcid":"https://orcid.org/0000-0003-1605-0734","observed_orcids":["https://orcid.org/0000-0003-1605-0734"]},"institutions":[{"id":"https://openalex.org/I12912129","display_name":"Northeastern University","ror":"https://ror.org/04t5xt781","country_code":"US","type":"education","lineage":["https://openalex.org/I12912129"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Srinivas Sridhar","raw_affiliation_strings":["Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA, USA","Nanomedicine Science and Technology Center, Northeastern University, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA, USA","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Nanomedicine Science and Technology Center, Northeastern University, Boston, MA, USA","institution_ids":["https://openalex.org/I12912129"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5101987852"],"corresponding_institution_ids":["https://openalex.org/I12912129","https://openalex.org/I4210117453"],"apc_list":{"value":2836,"currency":"USD","value_usd":2836},"apc_paid":{"value":2836,"currency":"USD","value_usd":2836},"fwci":0.2755,"has_fulltext":true,"cited_by_count":11,"citation_normalized_percentile":{"value":0.57605568,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"Volume 13","issue":"T-NANO 2014 Abstracts","first_page":"59","last_page":"61"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.6083999872207642,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.6083999872207642,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.357699990272522,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","score":0.009399999864399433,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.9959999918937683},{"id":"https://openalex.org/keywords/olaparib","display_name":"olaparib","score":0.996999979019165},{"id":"https://openalex.org/keywords/talazoparib","display_name":"talazoparib","score":0.9909999966621399},{"id":"https://openalex.org/keywords/nanoparticle-drug-delivery","display_name":"nanoparticle drug delivery","score":0.890999972820282},{"id":"https://openalex.org/keywords/dna-repair","display_name":"DNA repair","score":0.7429999709129333},{"id":"https://openalex.org/keywords/tumor-accumulation","display_name":"tumor accumulation","score":0.6600000262260437},{"id":"https://openalex.org/keywords/colony-formation","display_name":"colony formation","score":0.5889999866485596},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.5440000295639038},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6489999890327454}],"concepts":[{"id":"https://openalex.org/C2779962180","wikidata":"https://www.wikidata.org/wiki/Q7083106","display_name":"Olaparib","level":5,"score":0.993348240852356},{"id":"https://openalex.org/C2779138821","wikidata":"https://www.wikidata.org/wiki/Q7118227","display_name":"PARP inhibitor","level":5,"score":0.7986816167831421},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6241590976715088},{"id":"https://openalex.org/C134935766","wikidata":"https://www.wikidata.org/wiki/Q210538","display_name":"DNA repair","level":3,"score":0.5653306245803833},{"id":"https://openalex.org/C143425029","wikidata":"https://www.wikidata.org/wiki/Q5205747","display_name":"DNA damage","level":3,"score":0.5241425633430481},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.5241232514381409},{"id":"https://openalex.org/C2778480876","wikidata":"https://www.wikidata.org/wiki/Q21112674","display_name":"PARP1","level":5,"score":0.4606513977050781},{"id":"https://openalex.org/C2778502085","wikidata":"https://www.wikidata.org/wiki/Q7662767","display_name":"Synthetic lethality","level":4,"score":0.45658180117607117},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.451806902885437},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4309369623661041},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.412456214427948},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3217286169528961},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.24398177862167358},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.11911523342132568},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.09714603424072266}],"mesh":[{"descriptor_ui":"D000067856","descriptor_name":"Poly(ADP-ribose) Polymerase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000067856","descriptor_name":"Poly(ADP-ribose) Polymerase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010793","descriptor_name":"Phthalazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D010793","descriptor_name":"Phthalazines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D016503","descriptor_name":"Drug Delivery Systems","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D049329","descriptor_name":"Nanostructures","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D049329","descriptor_name":"Nanostructures","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.2147/ijn.s124992","doi":"https://doi.org/10.2147/ijn.s124992","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ijn.s124992","pdf_url":"https://www.dovepress.com/getfile.php?fileID=41002","source":{"id":"https://openalex.org/S101287785","display_name":"International Journal of Nanomedicine","issn_l":"1176-9114","issn":["1176-9114","1178-2013"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Nanomedicine","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:5863639","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5863639","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Int J Nanomedicine","raw_type":"Text"},{"id":"pmid:29593397","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29593397","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International journal of nanomedicine","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:5f6d8cd0e01943c2a743e1b6e2b71fde","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/5f6d8cd0e01943c2a743e1b6e2b71fde","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"International Journal of Nanomedicine, Vol Volume 13, Pp 59-61 (2018)","raw_type":"article"},{"id":"pmh:oai:dovepress.com/37255","doi":null,"is_oa":true,"landing_page_url":"https://www.dovepress.com/in-vitro-analysis-of-parp-inhibitor-nanoformulations-peer-reviewed-article-IJN","pdf_url":null,"source":{"id":"https://openalex.org/S4306401012","display_name":"Dove Medical Press (Taylor and Francis Group)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Short Report"}],"best_oa_location":{"id":"doi:10.2147/ijn.s124992","doi":"https://doi.org/10.2147/ijn.s124992","is_oa":true,"landing_page_url":"https://doi.org/10.2147/ijn.s124992","pdf_url":"https://www.dovepress.com/getfile.php?fileID=41002","source":{"id":"https://openalex.org/S101287785","display_name":"International Journal of Nanomedicine","issn_l":"1176-9114","issn":["1176-9114","1178-2013"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-140","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International Journal of Nanomedicine","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G2741768951","display_name":"IGERT Nanomedicine Science and Technology","funder_award_id":"0965843","funder_id":"https://openalex.org/F4320306076","funder_display_name":"National Science Foundation"},{"id":"https://openalex.org/G4774785343","display_name":null,"funder_award_id":"DGE-0965843","funder_id":"https://openalex.org/F4320337368","funder_display_name":"Division of Graduate Education"},{"id":"https://openalex.org/G7644268314","display_name":null,"funder_award_id":"0965843","funder_id":"https://openalex.org/F4320337368","funder_display_name":"Division of Graduate Education"}],"funders":[{"id":"https://openalex.org/F4320306076","display_name":"National Science Foundation","ror":"https://ror.org/021nxhr62"},{"id":"https://openalex.org/F4320337368","display_name":"Division of Graduate Education","ror":"https://ror.org/00whkrf32"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2789470100.pdf","grobid_xml":"https://content.openalex.org/works/W2789470100.grobid-xml"},"referenced_works_count":3,"referenced_works":["https://openalex.org/W2006001375","https://openalex.org/W2091814658","https://openalex.org/W2151499633"],"related_works":["https://openalex.org/W1992065025","https://openalex.org/W7070521202","https://openalex.org/W2079215618","https://openalex.org/W2566054689","https://openalex.org/W2563544855","https://openalex.org/W2504216116","https://openalex.org/W2572479995","https://openalex.org/W2528345273","https://openalex.org/W7060780813","https://openalex.org/W2399980135"],"abstract_inverted_index":{"PARP-l":[0],"is":[1,60,140],"a":[2,8,11,50,53,98,126,141,155],"DNA":[3,34],"repair":[4,14],"protein":[5],"that":[6,96,119,138],"plays":[7],"role":[9],"in":[10,19,63,76,84,101,109,157,167,173],"number":[12,54],"of":[13,42,52,55,92,122,150,164],"pathways":[15],"and":[16,29,67,124,133],"also":[17],"helps":[18],"transcriptional":[20],"regulation;":[21],"thus":[22],"PARP":[23],"inhibitors":[24,153],"(PARPi),":[25],"such":[26],"as":[27,49,154],"olaparib":[28,59,93,123],"BMN-673,":[30,125],"act":[31],"by":[32],"inhibiting":[33,158],"damage":[35],"repair.":[36],"This":[37],"leads":[38],"to":[39,46,73,80],"an":[40,64,88,134],"accumulation":[41,75],"deleterious":[43],"mutations":[44],"leading":[45,72],"genetic":[47],"instability":[48],"result":[51],"cell":[56],"replications.":[57],"Currently,":[58],"only":[61],"available":[62],"oral":[65],"form":[66],"has":[68],"poor":[69,74],"bioavailability,":[70],"consequently":[71],"the":[77,85,103,110],"tumor":[78,114],"due":[79],"first-pass":[81],"metabolism.":[82],"Therefore,":[83],"present":[86],"study,":[87],"injectable":[89,120],"nanoparticle":[90],"formulation":[91],"was":[94],"created":[95],"offers":[97],"delivery":[99],"route":[100],"which":[102,175],"drug":[104],"would":[105],"be":[106,131],"fully":[107],"bioavailable":[108],"vasculature,":[111],"suggesting":[112],"greater":[113],"accumulation.":[115],"Our":[116],"results":[117],"illustrated":[118],"nanoformulations":[121],"next":[127],"generation":[128],"PARPi,":[129],"could":[130],"developed,":[132],"efficacy":[135,163],"test":[136],"indicated":[137],"BMN-673":[139],"much":[142],"more":[143],"potent":[144],"PARPi":[145],"than":[146],"olaparib.":[147],"The":[148],"success":[149],"these":[151,165],"molecular":[152],"monotherapy":[156],"colony":[159],"formation":[160],"suggests":[161],"enhanced":[162],"treatments":[166],"combination":[168],"with":[169],"other":[170],"therapies,":[171],"even":[172],"tumors":[174],"have":[176],"developed":[177],"resistance.":[178]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1}],"updated_date":"2026-11-03T10:50:19.383937","created_date":"2018-03-29T00:00:00"}